ctDNA for Risk Stratification in Melanoma

This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with high-risk primary melanoma, potentially providing a baseline measurement for future disease monitoring.

NCT Number	NCT07531121
Lead Sponsor	Herlev and Gentofte Hospital Collaborators: Danish Cancer Society, Danish Cancer Research Foundation, DCCC ctDNA Research Center, CAG in Cancer immunotherapy
Conditions	Melanoma (Skin Cancer)
Enrollment	296 participants
Start Date	2021-09-10
Primary Completion	2025-05-20 (estimated)
Study Completion	2026-05-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-15